Drug intelligence / Profile preview

atezolizumab + durvalumab + ipilimumab + nivolumab + pembrolizumab

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This is a combination of five immune checkpoint inhibitors. Atezolizumab (Tecentriq) and durvalumab (Imfinzi) are PD-L1 inhibitors, while ipilimumab is a CTLA-4 inhibitor, and nivolumab and pembrolizumab are PD-1 inhibitors. These medications work by enhancing T-cell function and immune response against cancer cells. Each of these drugs has individual approvals for various cancer types including lung cancer, melanoma, and other solid tumors.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on atezolizumab + durvalumab + ipilimumab + nivolumab + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atezolizumab + durvalumab + ipilimumab + nivolumab + pembrolizumab.

Explore the full profile